Elicio’s Broad Cancer-Vaccine Ambitions

Initial clinical trial data highlight the potential for a new approach to cancer vaccines to treat patients with a wide range of KRAS mutations, Elicio Therapeutics CEO Robert Connelly explains. In this episode of the Vanguards of Health Care podcast, Connelly joins Bloomberg Intelligence biotech analyst Marc Engelsgjerd for a discussion of Elicio’s novel, lymph node-targeting vaccine platform, the company’s recent transition to the public markets via a reverse merger and the biotech scene in Boston’s booming Seaport district, where Elicio is based.  See omnystudio.com/listener for privacy information.